Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuvastatic for Cancer-Related Fatigue in Metastatic Colorectal Cancer
NCT07669454Phase 3Recruiting
- Sponsor
- Natureceuticals
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer-related fatigue (CRF) comparing Nuvastatic 300 with Placebo (2 arms). Primary endpoint: Reduction in cancer-related fatigue at 6 months. Started Oct 2025; status: recruiting.
02
Drugs
Nuvastatic
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on NCT07669454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07669454.